Guardant Health Q4 revenue up 39% driven by oncology and screening

Guardant Health

19/02/2026 21:23

Overview

Precision oncology firm's Q4 2025 revenue grew 39% yr/yr, driven by oncology and screening

Adjusted EPS for Q4 2025 beat analyst expectations

Outlook

Guardant Health expects full year 2026 revenue between $1.25 bln and $1.28 bln

Company anticipates 2026 Oncology revenue growth of 25% to 27%

Guardant Health forecasts 2026 Screening revenue between $162 mln and $174 mln

Result Drivers

ONCOLOGY GROWTH - Oncology revenue increased 30% in Q4 2025, driven by a 38% rise in test volumes

SCREENING EXPANSION - Screening revenue surged due to Shield test volume increase from 6,400 to 38,000 tests

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Beat
-$0.50
-$0.70 (14 Analysts)
Q4 Adjusted Net Income
Beat
-$63.80 mln
-$93.24 mln (12 Analysts)
Q4 Adjusted EBITDA
Miss
-$64.90 mln
-$49.88 mln (15 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Guardant Health Inc is $120.00, about 11.7% above its February 18 closing price of $107.42

Press Release: ID:nBw1wcH58a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)